Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Xiamen Amoytop Biotech Co., Ltd. (688278.SS)

75.00
+1.52
+(2.07%)
At close: 3:00:02 PM GMT+8
Loading Chart for 688278.SS
  • Previous Close 73.48
  • Open 72.80
  • Bid 75.00 x --
  • Ask 75.02 x --
  • Day's Range 72.80 - 75.34
  • 52 Week Range 46.30 - 88.38
  • Volume 3,417,191
  • Avg. Volume 3,113,128
  • Market Cap (intraday) 30.51B
  • Beta (5Y Monthly) 0.23
  • PE Ratio (TTM) 33.94
  • EPS (TTM) 2.21
  • Earnings Date --
  • Forward Dividend & Yield 0.41 (0.52%)
  • Ex-Dividend Date May 23, 2024
  • 1y Target Est --

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.

www.amoytop.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688278.SS

View More

Performance Overview: 688278.SS

Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688278.SS
2.22%
SSE Composite Index (000001.SS)
1.63%

1-Year Return

688278.SS
26.22%
SSE Composite Index (000001.SS)
8.29%

3-Year Return

688278.SS
195.46%
SSE Composite Index (000001.SS)
6.81%

5-Year Return

688278.SS
103.34%
SSE Composite Index (000001.SS)
17.40%

Compare To: 688278.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688278.SS

View More

Valuation Measures

Annual
As of 4/23/2025
  • Market Cap

    29.89B

  • Enterprise Value

    29.09B

  • Trailing P/E

    34.02

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.19

  • Price/Book (mrq)

    10.87

  • Enterprise Value/Revenue

    9.88

  • Enterprise Value/EBITDA

    29.58

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    29.38%

  • Return on Assets (ttm)

    22.36%

  • Return on Equity (ttm)

    39.97%

  • Revenue (ttm)

    2.82B

  • Net Income Avi to Common (ttm)

    827.6M

  • Diluted EPS (ttm)

    2.21

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    584.55M

  • Total Debt/Equity (mrq)

    0.44%

  • Levered Free Cash Flow (ttm)

    -33.11M

Research Analysis: 688278.SS

View More

Company Insights: 688278.SS

Research Reports: 688278.SS

View More

People Also Watch